US2003175796A1PendingUtilityA1

Diagnostic assay for antibiotic tolerance

Assignee: ST JUDE CHILDRENS RES HOSPITALPriority: Nov 13, 2001Filed: May 2, 2003Published: Sep 18, 2003
Est. expiryNov 13, 2021(expired)· nominal 20-yr term from priority
C07K 14/3156C12Q 1/689C12Q 2600/156C12Q 1/18
50
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Allelic variation in the vex2, pep27 and vncS genes of bacteria responsible for tolerance to antibiotics such as penicillin and vancomycin, is taught. Methods for identifying antibiotic tolerant bacteria and subjects infected with such bacteria, particularly antibiotic tolerant Streptococcus pneumoniae , are provided. Test kits and components useful for performing such methods, particularly including oligonucleotide primers, are also provided.

Claims

exact text as granted — not AI-modified
We claim:  
     
         1 . A method for determining whether a bacteria is likely to be tolerant to at least one antibiotic comprising 
 (a) determining whether said bacteria has a type 4 or R6 allele of the vex2 gene, and    (b) determining whether said bacteria has a type 4 or R6 allele of the pep27 gene, wherein said bacteria is determined to be likely to be tolerant if it has a type 4 allele of the vex2 gene and an R6 allele of the pep27.    
     
     
         2 . The method of  claim 1  wherein said antibiotic is a β lactam.  
     
     
         3 . The method of  claim 1  wherein said antibiotic is selected from the group consisting of penicillin and vancomycin.  
     
     
         4 . The method of  claim 1  wherein the step (a) is accomplished by determining the nucleotides present in the vex2 gene of said bacteria at the locations corresponding to nucleotides 41 and 67 of SEQ ID No. 1, and step (b) is accomplished by determining the nucleotides present in the pep27 gene of said bacteria at the locations corresponding to nucleotides 35 and 46 of SEQ ID No. 3.  
     
     
         5 . The method of  claim 4  wherein steps (a) and (b) are accomplished by sequencing a region of the genomic DNA of said bacteria which includes said locations.  
     
     
         6 . The method of  claim 4  wherein steps (a) and (b) are accomplished by (i) amplifying a region of the genomic DNA of said bacteria which includes said locations to generate an amplified fragment, and (ii) treating the amplified fragment with a restriction enzyme in its corresponding restriction buffer to determine the identity of the nucleotide present at the selected locations.  
     
     
         7 . The method of  claim 4  wherein steps (a) and (b) are accomplished by (i) amplifying a region of the genomic DNA of said bacteria which includes said locations, and (ii) hybridizing the amplified region with probes specific for the selected locations wherein hybridization determines the identity of the nucleotide present at the selected locations.  
     
     
         8 . The method of  claim 1  further comprising determining whether said bacteria has a wildtype or tolerant allele of the vncS gene, wherein said bacteria is also determined to be tolerant if it has the tolerant allele of the vncS gene.  
     
     
         9 . A method for determining the vex2 genotype of a selected bacteria comprising determining the identity of the nucleotides located at the positions corresponding to nucleotides 41 and 67 of SEQ ID No. 1 in the genomic DNA of said selected bacteria.  
     
     
         10 . The method of  claim 9  comprising the steps of: 
 (a) isolating nucleic acid from the bacteria;  
 (b) amplifying a region of the vex2 gene which includes the locations corresponding to nucleotides 41 and 67 of SEQ ID No. 1; and  
 (c) determining the identity of the nucleotides located at the positions corresponding to nucleotides 41 and 67 of SEQ ID No. 1.  
 
     
     
         11 . A method for determining the pep27 genotype of a selected bacteria comprising determining the identity of the nucleotides located at the positions corresponding to nucleotides 35 and 46 of SEQ ID No. 3 in the genomic DNA of said selected bacteria.  
     
     
         12 . The method of  claim 11  comprising the steps of: 
 (a) isolating nucleic acid from the bacteria;  
 (b) amplifying a region of the pep27 gene which includes the locations corresponding to nucleotides 35 and 46 of SEQ ID No. 3; and  
 (c) determining the identity of the nucleotides located at the positions corresponding to nucleotides 35 and 46 of SEQ ID No. 3.  
 
     
     
         13 . A test kit suitable for determining the vex2 and pep27 genotype of a bacteria thereby determining whether said bacteria is likely to be tolerant to at least one antibiotic comprising: 
 (a) a predetermined amount of a first amplification primer complementary to a region of the vex2 gene 5′ to the location corresponding to nucleotide 41 of SEQ IDNo. 1;    (b) a predetermined amount of a second amplification primer complementary to a region of the vex2 gene 3′ to the location corresponding to nucleotide 67 of SEQ ID No. 1; and    (c) a predetermined amount of a third amplification primer complementary to a region of the pep27 gene 5′ to the location corresponding to nucleotide 35 of SEQ ID No. 3; and    (d) a predetermined amount of a fourth amplification primer complementary to a region of the pep27 gene 3′ to the location corresponding to nucleotide 46 of SEQ ID No. 3;    (e) other reagents; and    (f) directions for use of said kit,    wherein said first amplification primer and said second amplification primer can be used to amplify a region of the vex 2 gene that distinguishes the type 4 and R6 alleles and said third amplification primer and said fourth amplification primer can be used to amplify a region of the pep27 gene that distinguishes the type 4 and R6 alleles.    
     
     
         14 . The kit of  claim 13  wherein said first amplification primer is SEQ ID No. 7, said second amplification primer is SEQ ID No. 8, said third amplification primer is SEQ ID No. 9, and said fourth amplification primer is SEQ ID No. 10.  
     
     
         15 . The kit of  claim 13  further comprising: 
 (g) a predetermined amount of a fifth amplification primer complementary to a region of the vncS gene 5′ to the location corresponding to nucleotide 79 of SEQ ID. No. 5; and  
 (h) a predetermined amount of a sixth amplification primer complementary to a region of the vncS gene 3′ to the location corresponding to nucleotide 79 of SEQ ID. No. 5,  
 wherein said fifth amplification primer and said sixth amplification primer can be used to amplify a region of the vncs gene that distinguishes the wildtype and tolerant alleles.  
 
     
     
         16 . The kit of  claim 15  wherein said fifth amplification primer is SEQ ID No. 11 and said sixth amplification primer is SEQ ID No. 12.

Join the waitlist — get patent alerts

Track US2003175796A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.